Phase 1/2a Trial of Gene Therapy Engensis for CMT1A Begins in Korea
Helixmith has launched a Phase 1/2 clinical trial in South Korea to investigate its gene therapy product Engensis (VM202) for the treatment of muscle symptoms in people with Charcot-Marie-Tooth disease (CMT) type 1A, the most common disease subtype. The trial was approved in April by South…